News

Progesterone largely ineffective in treatment of traumatic brain injuries


 

FROM THE NEW ENGLAND JOURNAL OF MEDICINE

References

“Despite extensive preclinical data and two promising single-center trials, progesterone was not associated with any benefit over placebo, as measured by the GOS-E score at 6 months, in this large, multicenter clinical trial,” wrote lead author Dr. David W. Wright of Emory University, Atlanta, and his associates.

“The PROTECT III trial joins a growing list of negative or inconclusive trials in the arduous search for a treatment for TBI. To date, no treatment has succeeded at the confirmatory trial stage,” the researchers noted.

The SYNAPSE trial was funded by BHR Pharma, a division of Besins Healthcare. PROTECT III was funded by the National Institutes of Health’s National Institute of Neurological Disorders and Stroke and the National Center for Advancing Translational Sciences; the Emory Emergency Neurosciences Laboratory at Emory University, Atlanta; and Grady Memorial Hospital, Atlanta. Several coauthors for each study had their own disclosures, as well.

dchitnis@frontlinemedcom.com

Pages

Recommended Reading

Return-to-play decisions a key challenge in management of sports-related concussion
MDedge Neurology
Position paper on sports-related concussion sets the right tone
MDedge Neurology
Mild TBI may predict PTSD, not postconcussion syndrome
MDedge Neurology
Frozen or powdered? Anticoagulation options in trauma are expanding
MDedge Neurology
Biomarker test may allow immediate diagnosis of concussion
MDedge Neurology
Vagal nerve blockade effects on morbid obesity warrant further study
MDedge Neurology
Traumatic brain injury in adolescence increases likelihood of harmful behavior
MDedge Neurology
Decompression can save lives in ventricular trapping
MDedge Neurology
Hyperbaric oxygen no better than placebo for treating postconcussion symptoms in military
MDedge Neurology
Palliative consult helps geriatric trauma patients avoid futile interventions
MDedge Neurology